Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800950 | 0.90 | RBP4 (0.39) | ADRA1AMCHR1RBP4KRASHPGDS | |
| SCHEMBL2800205 | 0.90 | RBP4 (0.46) | ADRA1AMCHR1RBP4KRASHPGDS | |
| SCHEMBL2800978 | 0.89 | ADRA1A (0.38) | ADRA1AMCHR1RBP4KRASHPGDS | |
| SCHEMBL2801080 | 0.86 | ALDH1A1 (0.36) | ALDH1A1HTR1AMAPTCYP46A1 | |
| SCHEMBL2799602 | 0.84 | IDO1 (0.33) | ALDH1A1 | |
| SCHEMBL2800842 | 0.83 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL2804334 | 0.83 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL2803802 | 0.82 | AVPR1A (0.37) | ALDH1A1HTR1AMAPT | |
| SCHEMBL2799537 | 0.81 | RECQL (0.36) | ALDH1A1MAPT | |
| SCHEMBL2801670 | 0.81 | FASN (0.39) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | ADRA1A 3142/4885MCHR1 3678/4885RBP4 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.